Outcome of three-dimensional conformal radiotherapy for early stage non-small cell lung cancer patients who met or not inclusion criteria for stereotactic-body radiation therapy;Wyniki konformalnej radioterapii chorych na niedrobnokomórkowego raka p uca we wczesnym stopniu zaawansowania spe niających kryteria oraz niespe niających kryteriów kwalifikacji do napromieniania stereotaktycznego

Pneumonologia i Alergologia Polska

Volumn 79, Issue 5, 2011, Pages 326-336

  Kolodziejczyk, Milena ^a   Kepka, Lucyna ^a   Tyc Szczepaniak, Dobromira ^a   Wierzchowski, Marek ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Conformal radiotherapy; Early stage; Non small cell lung cancer; Radiotherapy; SBRT

Indexed keywords

EID: 80052069475     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Spiro S.G., Porter J.C. Lung cancer where are we today? Current advances in staging and nonsurgical treatment. Am. J. Respir. Crit. Care Med. 2002; 166: 1166-1196.
2. Brown J.S., Eraut D., Trask C., Davison A.G. Age and the treatment of lung cancer. Thorax 1996; 51: 564-568.
3. Ulutin C., Aksu G. Radiotherapy and surgery in the management of non-small cell lung cancer in the elderly patients, a review of the recent literature. Cancer Therapy 2005; 3: 95-100.
4. Szczuka I., Roszkowski-Śliz K. Rak p uca w Polsce w latach 1970-2004. Pneumonol. Alergol. Pol. 2008; 76: 19-28.
5. Jeremic B., Classen J., Bamberg M. Radiotherapy alone in technically operable, medically inoperable, early-stage (I/II) non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002; 54: 119-130.
6. Chi A., Liao Z., Nguyen N.P., Xu J., Stea B., Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother. Oncol. 2010; 94: 1-11.
7. Timmerman R., McGarry R., Yiannoutsos C. I wsp. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J. Clin. Oncol. 2006; 24: 4833-4839.
8. Greene F.L., Page D.L., Fleming I.D. I wsp. Lung. W: AJCC Cancer staging manual. 6supth/sup Edition. Springer-Verlag, New York, 2002: 167-177.
9. International Commission on Radiation Units and Measurements. ICRU Report 62. Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50). Bethesda, 1999.
10. Fowler J.F. Biological factors influencing optimum fractionation in radiation therapy. Acta Oncol. 2001; 40: 712-717.
11. www.rtog.org/members/RTOG0236:a_phase_II_trial_of_stereo-tactic_body_radiation_therapy_(SBRT)_in_the_treatment_of_patients_with_medically_inoperable_stage_I/II_non-small_cell_lung_cancer.Protocols/0236/0.236.pdf
12. Bradley J.D., Ieumwananonthachai N., Purdy J.A. I wsp. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2002; 52: 49-57.
13. Ball D.L., Smith J., Wirth A. I wsp. Failure of T stage to predict survival in patients with non-small-cell lung cancer treated by radiotherapy with or without concomitant chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2002; 54: 1007-1013.
14. Etiz D., Marks L.B., Zhou S.M. I wsp. Influence of tumor volume on survival in patients irradiated for non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002; 53: 835-846.
15. Basaki K., Abe Y., Aoki M., Kondo H., Hatayama Y., Nakaji S. Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. Int. J. Radiat. Oncol. Biol. Phys. 2006; 64: 449-454.
16. Kepka L., Tyc-Szczepaniak D., Bujko K. Dose-per-fraction escalation of accelerated hypofractionated three-dimensional con-formal radiotherapy in locally advanced non-small cell lung cancer. J. Thorac. Oncol. 2009; 4: 853-861.
17. Martel M., Ten Haken R., Hazuka M.B. I wsp. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 1999; 24: 31-37.
18. Mehta M., Scrimger R., Mackie R., Palliwal B., Chappell R., Fowler J. A new approach to dose escalation in non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2001; 49: 23-33.
19. Slotman B.J., Antonisse I.E., Njo K.H. Limited field irradiation in early stage (T1-2N0) non-small cell lung cancer. Radiother. Oncol. 1996; 41: 41-44.
20. Fakiris A.J., McGarry R.C., Yiannoutsos C.T. I wsp. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int. J. Radiat. Oncol. Biol. Phys. 2009; 75: 677-682.
21. Kepka L. Dylematy radykalnego leczenia onkologicznego chorych na raka p uca wokresie starości. Pneumonol. Alergol. Pol. 2009; 77: 166-172.
22. Belderbos J.S.A., Kepka L., Kong F.-M., Martel M.K., Videtic G.M.M., Jeremic B. Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: Non-Small Cell Lung Cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys. 2008; 72: 335-342.
23. Koodziejczyk M., Kepka L., Dziuk M. I wsp. Impact of [sup18/supF]fluorodeoxyglucose PET-CT staging on treatment planning in radiotherapy incorporating elective nodal irradiation for non-small cell lung cancer: a prospective study. Int. J. Radiat. Oncol. Biol. Phys. 2011; 80: 1008-1014.